HCPCS Level II code J2351 denotes the injection of ocrelizumab, 1 mg, combined with hyaluronidase-ocsq. The code identifies a therapeutic biologic administration relevant to neurology and infusion therapy practices and is used in billing for outpatient infusion or clinic-based injectable services. Nationally, accurate coding for high-cost biologics such as ocrelizumab affects payer reimbursement, care coordination, and drug utilization tracking.

Key payers covered include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find benchmarks and clarity on clinical context for use of this HCPCS Level II code, common billing considerations, and the typical sites where the service is provided. The publication outlines how J2351 is applied in billing lines, highlights common modifiers and payer reporting conventions (where available), and summarizes implications for billing workflows and claims processing. Data not available in the input is noted where relevant.